Literature DB >> 18085675

Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group.

A Lindsay Frazier1, Pavlina Rumcheva, Thomas Olson, Roger Giller, Barbara Cushing, John Cullen, Neyssa Marina, Wendy B London.   

Abstract

BACKGROUND: The purpose of this analysis is to explore whether the International Germ Cell Classification Consensus (IGCCC) tumor marker criteria, developed for adult males with metastatic malignant germ cell tumors (MGCT), are prognostic among pediatric patients and whether tumor marker data may be relevant in pediatric risk stratification. PROCEDURE: The IGCCC was applied to 436 pediatric germ cell patients treated on Pediatric Intergroup Studies from 1990 to 1996. Multivariable Cox proportional hazards model identified prognostic variables; survival rates among IGCCC risk groups were compared using the log-rank test. Concordance and relative performance of IGCCC versus COG risk stratification was evaluated.
RESULTS: Applying the IGCCC, 21% of pediatric patients were good risk (GR), 35% intermediate risk (IR), and 44% poor risk (PR). Only modest concordance between IGCCC and COG stratification systems was noted (49%). Nonetheless, the IGCCC identified a group of PR patients who had significantly worse event-free survival (EFS) versus GR/IR patients (6-year EFS 80% vs. 91%), which was similar to the difference observed using the COG system (6-year EFS 77% vs. 90%). The IGCCC performed well within subgroups for which the IGCCC is not intended (prepubertal, female, and non-metastatic patients).
CONCLUSIONS: Applying the IGCCC system to pediatric patients produces a different stratification than does the application of the COG system, although both are prognostic. Development of a de novo pediatric prognostic classification is warranted. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085675      PMCID: PMC3836436          DOI: 10.1002/pbc.21304

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

1.  Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.

Authors:  Neyssa Marina; Wendy B London; A Lindsay Frazier; Stephen Lauer; Frederick Rescorla; Barbara Cushing; Marcio H Malogolowkin; Robert P Castleberry; Richard B Womer; Thomas Olson
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

2.  Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age.

Authors:  M E Blohm; D Vesterling-Hörner; G Calaminus; U Göbel
Journal:  Pediatr Hematol Oncol       Date:  1998 Mar-Apr       Impact factor: 1.969

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Prognostic factors in children with localized malignant nonseminomatous germ cell tumors.

Authors:  M C Baranzelli; A Kramar; E Bouffet; E Quintana; H Rubie; C Edan; C Patte
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

5.  The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.

Authors:  J R Mann; F Raafat; K Robinson; J Imeson; P Gornall; M Sokal; E Gray; P McKeever; J Hale; S Bailey; A Oakhill
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

6.  Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89.

Authors:  G Calaminus; D T Schneider; J P M Bökkerink; H Gadner; D Harms; R Willers; U Göbel
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

7.  Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.

Authors:  D J Sonneveld; H J Hoekstra; W T van der Graaf; W J Sluiter; N H Mulder; P H Willemse; H S Koops; D T Sleijfer
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

8.  Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.

Authors:  Paul C Rogers; Thomas A Olson; John W Cullen; Deborah F Billmire; Neyssa Marina; Frederick Rescorla; Mary M Davis; Wendy B London; Stephen J Lauer; Roger H Giller; Barbara Cushing
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

9.  Serum alpha fetoprotein (AFP) levels in normal infants.

Authors:  J T Wu; L Book; K Sudar
Journal:  Pediatr Res       Date:  1981-01       Impact factor: 3.756

10.  Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.

Authors:  Barbara Cushing; Roger Giller; John W Cullen; Neyssa M Marina; Stephen J Lauer; Thomas A Olson; Paul C Rogers; Paul Colombani; Frederick Rescorla; Deborah F Billmire; Charles D Vinocur; Edith P Hawkins; Mary Margaret Davis; Elizabeth J Perlman; Wendy B London; Robert P Castleberry
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

  10 in total
  8 in total

Review 1.  Extracranial malignant germ cell tumors.

Authors:  Yogesh Kumar Sarin; Sushmita Nitin Bhatnagar
Journal:  Indian J Pediatr       Date:  2012-06-16       Impact factor: 1.967

2.  Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States.

Authors:  A Lindsay Frazier; Juliet P Hale; Carlos Rodriguez-Galindo; Ha Dang; Thomas Olson; Matthew J Murray; James F Amatruda; Claire Thornton; G Suren Arul; Deborah Billmire; Furqan Shaikh; Farzana Pashankar; Sara Stoneham; Mark Krailo; James C Nicholson
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

3.  Survival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis.

Authors:  Arnav Srivastava; Hiren V Patel; Elizabeth Koehne; Gopal N Gupta; Richard Drachtman; Phillip M Pierorazio; Aditya Bagrodia; Sammy E Elsamra; Isaac Y Kim; Saum Ghodoussipour; Eric A Singer; Thomas L Jang; Hiten D Patel; Joseph G Barone
Journal:  Urol Oncol       Date:  2022-02-08       Impact factor: 3.498

Review 4.  Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Authors:  Thomas A Olson; Matthew J Murray; Carlos Rodriguez-Galindo; James C Nicholson; Deborah F Billmire; Mark D Krailo; Ha M Dang; James F Amatruda; Claire M Thornton; G Suren Arul; Sara J Stoneham; Farzana Pashankar; Daniel Stark; Furqan Shaikh; David M Gershenson; Allan Covens; Jean Hurteau; Sally P Stenning; Darren R Feldman; Peter S Grimison; Robert A Huddart; Christopher Sweeney; Thomas Powles; Luiz Fernando Lopes; Simone dos Santos Agular; Girish Chinnaswamy; Sahar Khaleel; Sherif Abouelnaga; Juliet P Hale; A Lindsay Frazier
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 5.  Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Authors:  John A Sandoval; Linda H Malkas; Robert J Hickey
Journal:  Int J Mol Sci       Date:  2012-01-20       Impact factor: 6.208

Review 6.  Diagnostic, Prognostic and Predictive Markers in Pediatric Germ Cell Tumors-Past, Present and Future.

Authors:  Michalina Jezierska; Ada Gawrychowska; Joanna Stefanowicz
Journal:  Diagnostics (Basel)       Date:  2022-01-21

7.  Prognostic factors in children with extracranial germ cell tumors treated with cisplatin-based chemotherapy.

Authors:  Jinsup Kim; Na Hee Lee; Soo Hyun Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Jeong-Meen Seo; Suk-Koo Lee
Journal:  Korean J Pediatr       Date:  2015-10-21

8.  Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology.

Authors:  Gabriele Calaminus; Dominik T Schneider; Dietrich von Schweinitz; Heribert Jürgens; Nacera Infed; Stefan Schönberger; Thomas A Olson; Peter Albers; Christian Vokuhl; Raimund Stein; Leendert Looijenga; Jalid Sehouli; Martin Metzelder; Alexander Claviez; Michael Dworzak; Angelika Eggert; Birgit Fröhlich; Nicolas U Gerber; Christian P Kratz; Jörg Faber; Thomas Klingebiel; Dieter Harms; Ulrich Göbel
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.